Binex is likely to be removed from the KPBMA member list

The meeting of the chairman and the directors on the 16th, deciding whether to refer to the ethics committee

2013 Wales Korea Pharm's first expulsion precedent, likely to follow the procedure of suspension of qualification → voluntary withdrawal

Immediate decision after convening of ethics committee within a few days

The KPBMA

It is observed that Binex, which is suspected of changing the manufacturing of active pharmaceutical ingredients, has a strong expulsion from the KPBMA membership.

 

The KPBMA is expected to hold a meeting of the board of directors on the 16th and refer the agenda on the Binex situation to the ethics committee.

 

In a statement on the 11th, the KPBMA is highly likely to convene an ethics committee with the unanimous opinion of 14 directors and presidents in order to degrade K-Bio status and protect the right to public health.

 

If the board of directors' opinion is gathered on this day, the ethics committee will convene within 3 days at the latest, and it is expected that a prompt decision will be made.

 

Since the establishment of the KPBMA in 1945, Wales Korea has the only precedent for the withdrawal of regular members.

 

Wales Korea was expelled from the KPBMA by changing the date of manufacture of the drug that expired in 2013.

 

Pharmaking was prosecuted by the prosecution for a rebate in 2016 and voluntarily withdrew after being suspended from qualification by the association's ethics committee.

 

If Binex is subject to disqualification, it will be the second expulsion case ever.

 

However, the Ethics Committee may consider the pharmacy precedent as much as possible and refine it to suspension of qualifications rather than expulsion or forced withdrawal.

 

Binex joined the association in 1957 under the name of the former Suncheondang and has been active as a member for 65 years.

 

The ethics committee is chaired by Yun Sung-tae, vice-chairman of Huons Global, and consists of 7 members, including President Oh Heung-ju, DongKook (Vice Chairman) and Lee Won-beom, CEO of Whanin (a member).

 

Looking at the membership management regulations of the association,'The chairman may request a deliberation by the ethics committee when it is recognized that a member has a reason for disciplinary action in the articles of association.

 

The association shall notify the member in writing of the fact of the claim and the grounds for disciplinary action recognized, and give them an opportunity to clarify.' Therefore, Binex of the Ethics Committee, a member of the Pharmaceutical Association, has the strongest force.

 

The meeting of the chairman and the directors on the 16th, deciding whether to refer to the ethics committee 2013 Wales Korea Pharm's first expulsion precedent, likely to follow the procedure of suspension of qualification → voluntary withdrawal.

 

Immediate decision after convening of ethics committee within a few days, unanimous public opinion rises.

 

It is observed that Binex, which is suspicious of a change in the manufacture of the main ingredient of pharmaceuticals, is likely to be expelled from The KPBMA as a full member.

 

The KPBMA is expected to hold a meeting of the board of directors on the 16th and refer to the Binex situation to the ethics committee.

 

In a statement on the 11th, the KPBMA is highly likely to convene an ethics committee with the unanimous opinion of 14 directors and presidents in order to degrade K-Bio status and protect the right to public health.

 

If the board of directors' opinion is gathered on this day, the ethics committee will convene within 3 days at the latest, and it is expected that a prompt decision will be made.

 

Since the establishment of The KPBMA in 1945, Wales Korea Pharm has the only precedent for the withdrawal (dismissal) of regular members.

 

Wales Korea Pharm was expelled from the Association by changing the date of manufacture of the drug that expired in 2013.

 

Afterwards, Pharmaking, who was prosecuted by the prosecution for a rebate in 2016, voluntarily withdrew after being suspended from qualification by the association's ethics committee.

 

If Binex is subject to disqualification, it will be the second expulsion case ever.

 

However, the Ethics Committee may consider the pharmacy precedent as much as possible and refine it to suspension of qualifications rather than expulsion or forced withdrawal.

 

Binex joined the association in 1957 under the name of the former Suncheondang Pharmaceutical Company and has been active as a member for 65 years.

 

Meanwhile, the ethics committee is chaired by Yun Sung-tae, vice-chairman of Huons Global, and consists of 7 members, including President Oh Heung-ju, DongKook (Vice Chairman) and Lee Won-beom, Whanin President (Committee).

 

Looking at the membership management regulations of the association,'The chairman may request a deliberation by the ethics committee when it is recognized that a member has a reason for disciplinary action in the articles of association.

 

The association shall notify the member in writing of the fact of the claim and the grounds for disciplinary action recognized, and give them an opportunity to clarify.' Therefore, when or after the convocation of the Ethics Committee this time, attention is also being paid to whether Binex's executives will appear in person to explain the overall situation or replace them in writing.